Bpifrance

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

H'ability specializes in providing immersive virtual reality (VR) therapeutic exercises that complement traditional rehabilitation methods. The company offers a wireless VR headset with customizable exercises targeting motor skills, balance, and cognitive functions. Their platform features real-time session personalization, detailed progress tracking with data analytics, and compatibility with additional rehabilitation tools. This enables healthcare professionals to deliver personalized, engaging, and efficient therapy sessions in clinical settings or at patients' homes, catering to various medical conditions.

Parallel builds AI agents that streamline healthcare admin workflows, seamlessly integrated to unlock efficiency at scale.

Fizimed SAS is a French company based in Strasbourg that specializes in developing medical devices aimed at addressing urinary incontinence in women. The company's flagship product, EMY, is a perineal probe designed to facilitate pelvic floor muscle reeducation. EMY connects to a mobile application, allowing users to engage in customized, interactive exercises that strengthen their pelvic floor while tracking their progress in real time. The device incorporates gamified elements to motivate users, offering various activities that turn exercises into enjoyable challenges. Founded in 2017, Fizimed is committed to balancing the safety and quality of medical devices with user-friendly technology, while actively working to destigmatize urinary incontinence—a common issue affecting one in ten women. Through social media initiatives, Fizimed fosters a community that encourages open discussions around this topic, aiming to empower women to take control of their health and well-being.

MSInsight is a bioinformatics startup specializing in the development of diagnostic and treatment response prediction solutions for microsatellite instability (MSI) cancers. The company offers a platform that utilizes next-generation sequencing data to analyze MSI status, a crucial biomarker in oncology. By providing actionable insights on this biomarker, MSInsight enables healthcare professionals to make informed decisions about patient care, particularly concerning treatment options such as immunotherapy. The focus on diagnostic and prognostic biomarkers of treatment response enhances the ability to improve overall patient outcomes in the oncology market.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

MB Therapeutics is a pharmaceutical company specializing in personalized medicine. It offers a patient-centric system for developing and producing customized medications, including evaluation services. The company excels in tailoring medication dosage, forms, and combining multiple active ingredients into a single unit, enabling healthcare professionals to enhance treatment precision and improve patient adherence.

EG 427 is a French biotechnology company that specializes in a novel approach to gene therapy known as pinpoint gene therapy. The company focuses on developing HSV-1-based vectors, leveraging the natural characteristics of Herpes Simplex Virus 1 to create targeted and long-lasting expression of therapeutic genes. This innovative method aims to address spinal cord injury-related disorders, particularly neurogenic bladder conditions, by providing physicians with a potential cure for patients suffering from severe, chronic, and localized diseases. Through its advanced research, EG 427 seeks to transform treatment options for individuals affected by these challenging medical issues.

Ochy is a mobile application that leverages video and artificial intelligence to deliver lab-quality analysis of running techniques, allowing users to assess their performance anytime and anywhere. The app's core technology focuses on analyzing human movement, utilizing algorithms to evaluate biomechanical correctness during running. By identifying an individual's weak points, Ochy generates personalized exercise plans aimed at enhancing performance and preventing injuries. The platform is designed for a diverse user base, including runners without coaches seeking to refine their technique, coaches aiming to better understand and train their athletes, and medical professionals who need to evaluate their patients' movement for rehabilitation purposes. Through its innovative approach, Ochy empowers users to improve their running efficiency and overall athletic performance.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to overcome treatment resistance and enhance cancer cell survival. Their primary focus is on providing effective treatments for gastrointestinal cancers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Biolevate is an AI-driven company focused on enhancing the healthcare sector through advanced technology. It provides innovative solutions for researchers and medical professionals by automating essential tasks such as document generation and literature monitoring. By leveraging sophisticated AI algorithms, Biolevate enables effective knowledge management that streamlines research workflows and accelerates scientific discovery. The company's tools intelligently filter extensive datasets, prioritizing relevant scientific information and offering customizable search options along with insightful data visualizations. Through this approach, Biolevate empowers clients to make informed decisions and facilitates significant advancements in medical research, ultimately aiming to improve patient care.

Theremia is a health technology company that leverages artificial intelligence to transform drug development, with a focus on neurological disorders. It employs advanced machine learning to optimize drug compounds for specific demographic groups, enhancing treatment effectiveness and reducing adverse effects.

Doado is a health technology company that specializes in developing mobile applications for back health management. Its primary product is an e-health application designed to guide users step by step in improving their back health and preventing Musculoskeletal Disorders. The application offers personalized video programs, expert advice from physiotherapists and doctors, and AI-driven progress tracking, enabling individuals and companies to maintain an active lifestyle and reduce the risk of chronic back pain.

Skezi is an e-cohort startup that believes that valuing the voices of patients, caregivers, families, and carers would enhance future health. SKEZI offers solutions adapted to all sectors of sensitive data through its subscription offer to its SaaS platforms.

Vaxinano is a biotechnology company founded in 2016, focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Building on 25 years of research and clinical trials led by Pr Didier Betbeder, Vaxinano specializes in creating prophylactic and therapeutic vaccines for infectious diseases. The company employs safe-by-design nanoparticles that adhere to green chemistry principles, facilitating the development of drugs targeting active biomolecules, proteins, and antigens. This innovative approach enables medical researchers to create new vaccines aimed at addressing untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on the clinical development of first-in-class drug candidates aimed at treating and preventing diseases affecting pets, including periodontitis, osteoarthritis, and gut motility disorders. By prioritizing the creation of effective treatments for common health issues, Vetbiolix aims to enhance the quality of life for pets and their owners.

Hepta Medical is a medical technology company focused on developing innovative treatments for early lung cancer through minimally invasive, nonsurgical methods. The company's flagship product is a microwave ablation platform that employs a specialized catheter equipped with an integrated temperature sensor. This technology allows healthcare professionals to monitor and control the ablation volume in real-time, enhancing the precision of the treatment. By enabling targeted ablation while managing the size of the lesion, Hepta Medical aims to improve patient outcomes and increase the safety and efficiency of cancer therapies.

Archeon Medical specializes in the development of innovative solutions aimed at enhancing the monitoring, diagnosis, and treatment of critically ill patients during prehospital care. The company utilizes artificial intelligence to create disruptive technologies that focus on improving ventilation quality in emergency medical services. Archeon Medical's products are practical, easy to use, and intuitive, providing emergency caregivers with real-time feedback on the quality of ventilation administered to patients. Through its commitment to advancing prehospital care, Archeon Medical seeks to optimize patient outcomes in critical situations.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

StarkAge Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients through innovative treatments. The company specializes in developing a platform that utilizes immunotherapy combined with cancer therapy to target and deplete senescent cells associated with age-related diseases. Its research and development efforts are aimed at addressing conditions such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunctions, including hepatic fibroses. By leveraging its unique approach, StarkAge Therapeutics seeks to provide effective therapeutic options for managing these challenging health issues.

Biodol Therapeutics SAS is a biotechnology company based in Clapiers, France, established in 2015. The company focuses on developing innovative compounds for the treatment of chronic pain, specifically targeting the Receptor Tyrosine Kinase (RTK) FLT3, which plays a critical role in triggering and sustaining chronic neuropathic pain. Biodol Therapeutics' research indicates that inhibiting FLT3 can enhance the effectiveness of opioids, potentially reducing their risk of addiction and contributing to solutions for the opioid crisis. By creating extracellular inhibitors of the FLT3 receptor, the company aims to alleviate pain hypersensitivity, allodynia, and spontaneous pain while preserving normal nervous system function. Through academic partnerships, Biodol Therapeutics continues to advance its understanding of pain mechanisms and develop its proprietary therapeutic approaches.

MaaT Pharma, based in Lyon, France, is a clinical-stage biotechnology company founded in 2014 that specializes in the development of microbiome-based therapies aimed at treating diseases associated with gut microbiota imbalance. The company focuses on improving survival outcomes in patients with life-threatening conditions, particularly cancers and Graft-versus-Host Disease, a serious complication following allogeneic stem cell transplantation. MaaT Pharma has demonstrated proof of concept in acute myeloid leukemia patients and is actively expanding its pipeline to enhance outcomes in immunotherapy for solid tumors. Central to its research efforts is the GutPrint® platform, which facilitates the evaluation of drug candidates, identification of novel disease targets, and discovery of biomarkers related to microbiome-associated conditions.

Hephaistos Pharma is a biotechnology firm dedicated to advancing oncology treatments through innovative immunotherapy solutions. The company focuses on developing next-generation therapies that utilize active and non-specific immuno-stimulants, which enhance the efficacy of existing antibodies and transform cold tumors into hot targets for the immune system. By addressing unmet medical needs, Hephaistos Pharma aims to provide effective treatment options for patients with incurable cancers. Their platform is designed to stimulate immune responses, thereby improving the overall efficiency of immunotherapy. The firm also offers an online inquiry form on its website for further engagement.

May Health is a healthcare company focused on addressing infertility related to Polycystic Ovary Syndrome (PCOS). The company has developed an innovative, minimally invasive procedure aimed at restoring ovulation in women with PCOS. This one-time treatment is performed transvaginally under ultrasound guidance, allowing for its execution in a clinical setting without the need for general anesthesia. May Health's approach seeks to provide patients with a more natural pregnancy experience by assisting the body to ovulate as it would naturally, thereby offering a less medicalized alternative to traditional fertility treatments.

Klineo is a healthcare platform focused on enhancing access to clinical trials for oncology patients. It features an intuitive and intelligent search interface that caters to both healthcare professionals and patients. The platform allows users to efficiently locate relevant clinical trials for specific conditions such as breast, skin, and lymphoma cancers, facilitating contact with trial centers and improving the overall trial search experience. By connecting patients and doctors with appropriate clinical research opportunities, Klineo aims to streamline the process of finding critical treatment options in the oncology field.

Pixacare is a developer of a medical imaging application that enhances wound care management for healthcare professionals. This secure platform automates medical photo management and centralizes critical data for monitoring wounds, making it user-friendly and accessible on both mobile and desktop devices. Designed as a Class I CE-marked digital medical device, Pixacare's application transforms any smartphone camera into a secure documentation tool, enabling home-care staff, surgeons, and dermatologists to effectively monitor and anticipate complications in chronic and post-surgery wounds. By integrating seamlessly with healthcare infrastructures, including Patient Administration Systems and Electronic Health Records, Pixacare ensures data security through hosting on a certified Health Data Hosting server, thereby optimizing the workflow of medical professionals.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. By utilizing a non-ionizing three-dimensional (3D) imaging approach, HawkCell employs specialized MRI sensors designed to accommodate various animal morphologies. The company enhances its services with artificial intelligence algorithms, transforming traditional human MRI technology into dedicated imaging resources tailored for animal diagnostics and scientific exploration. This innovative approach provides veterinary clinics and research labs with precise and insightful tools for improving animal healthcare and advancing research initiatives.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in manufacturing computer-assisted surgery solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces innovative surgical navigation tools designed to control the positioning of implants with millimeter precision in three-dimensional space. Its proprietary camera technology, which can be integrated into smartphones or glasses, aids healthcare professionals in performing orthopedic surgeries effectively and affordably, addressing the challenges within the healthcare system.

I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Ochy is a mobile application that leverages video and artificial intelligence to deliver lab-quality analysis of running techniques, allowing users to assess their performance anytime and anywhere. The app's core technology focuses on analyzing human movement, utilizing algorithms to evaluate biomechanical correctness during running. By identifying an individual's weak points, Ochy generates personalized exercise plans aimed at enhancing performance and preventing injuries. The platform is designed for a diverse user base, including runners without coaches seeking to refine their technique, coaches aiming to better understand and train their athletes, and medical professionals who need to evaluate their patients' movement for rehabilitation purposes. Through its innovative approach, Ochy empowers users to improve their running efficiency and overall athletic performance.

Huvy is a company that utilizes artificial intelligence to enhance dermatological treatment pathways and provide essential medical information in real-time. It has developed a skin cancer screening application aimed at identifying cancer risks. This application facilitates dermatological screenings, particularly benefiting populations in areas with limited access to medical services. By offering initial diagnostic orientation, Huvy's technology enables patients to receive timely care if there is a suspicion of skin cancer, thus improving early detection and treatment outcomes.

Callyope is a technology company focused on enhancing brain health monitoring through human-centered solutions. By developing a speech-based platform that utilizes natural language processing and signal processing techniques, Callyope enables caregivers to monitor patients' brain functionality more effectively. The platform allows for a detailed examination of patients' verbal productions, providing valuable insights that help identify relapses and inform treatment decisions. Ultimately, Callyope aims to improve the quality of life for patients while also contributing to a reduction in re-hospitalization rates.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Steto Its mission is to create solutions for remote patient monitoring and digital diabetes therapies.

Astraveus is a pioneering company specializing in the manufacture of Cell & Gene Therapies (CGTs). It operates the Lakhesys™ platform, an innovative end-to-end solution that optimizes CGT production using single-use microfluidic bioprocessors. This approach reduces infrastructure requirements, lowers costs, and mitigates logistical challenges, aiming to enhance patient access to life-changing therapies while minimizing environmental impact.

Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide semi-quantitative counts of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy and speed of microbial contamination detection, facilitating more efficient screening and data collection in research and testing environments.

BariaTek is a company specializing in innovative bariatric surgery solutions. It focuses on providing minimally invasive procedures that utilize trans-oral access techniques and implantable devices through endoscopy. By doing so, BariaTek aims to replicate the effects of traditional bariatric surgery while minimizing patient discomfort and recovery time. This approach allows patients to receive effective treatment for obesity and related diseases in a less invasive manner, thereby enhancing the overall patient experience and outcomes.

EverImmune is a biotechnology company dedicated to developing innovative treatments in the field of microbiome oncology to support cancer patients. The company specializes in creating live biotherapeutic products that serve as oral adjuvants to enhance anticancer immunotherapies. By focusing on technologies that safely boost the immune system, EverImmune aims to restore sensitivity to immunotherapies, particularly in patients experiencing primary resistance. The company is committed to conducting well-designed clinical trials to evaluate the efficacy of its flagship product, Oncobax, in improving treatment outcomes for cancer patients.

Resolve Stroke, headquartered in Paris, is a HealthTech company dedicated to revolutionizing medical imaging. It specializes in enhancing ultrasound technology to extract more detailed information, enabling advanced diagnostics, particularly in neurology. The company's innovative software engines improve ultrasound contrast, resolution, and penetration depth, allowing for the visualization of micro-vessels through the human skull in 3D. With a global focus, Resolve Stroke aims to accelerate treatments for over 1 billion people affected by brain diseases. To date, it has secured €3 million in pre-seed funding to pioneer software-based ultrasound innovation.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

Teale is a prominent digital mental health platform that integrates psychology and technology to facilitate mental health care for individuals and organizations. The company offers personalized and engaging digital healthcare solutions, emphasizing the importance of subconscious well-being. Teale's approach includes individual support and collective workshops tailored to the specific needs of users, thereby enhancing the effectiveness of mental health initiatives. Through its curated network of mental health experts, Teale enables employees to assess their mental health status and access customized digital programs designed to promote their psychological resilience.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Pollen Robotics is a robotics company focused on developing humanoid service robots designed for interaction and manipulation of objects across various industries such as healthcare, retail, and education. Their robots are customizable and equipped with advanced robotic arms, enabling them to convey emotions through technology and antennas, thereby expanding potential applications and accessibility in the field of robotics.

Give smart ears to product. Saas B2B of an embedded AI to detect distress sounds (applied first to telecare companies).

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

SMAIO is a manufacturer of medical devices for spinal pathologies. They provide control over surgical procedures to the spine physician through a range of solutions.

Numa Health is a medical bioinformatics health technology company that focuses on empowering individuals to optimize their health capital and well-being. It has developed a digital health platform that offers tools designed to enhance users' commitment to their health. This platform facilitates the reinterpretation of blood test results, providing insights into bodily functions and overall health. By enabling users to measure, understand, and take actionable steps regarding their health, Numa Health aims to support individuals in their journey towards better health management.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

IA Medical transforms raw data into intelligent patient knowledge. Its algorithms help to understand patient data, from diagnosis to follow-up, to support them with its conversational agents but also to set up a hybrid solution of cognitive and behavioral therapies.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The firm aims to create medicinal chemistry solutions that have the potential to significantly improve the lives of cancer patients and their families. By employing a first-in-class approach, Kairos Discovery targets essential cellular mechanisms that contribute to the survival and aggressiveness of both solid tumors and hematological cancers. This commitment to breakthrough oncology technology positions the company as a key player in the advancement of cancer treatment.

Maddie is a healthcare technology company that offers software solutions designed for physiotherapists and other health professionals. Its platform enables effective practice management through features such as dematerialized diaries, online appointment bookings, and customizable websites. These tools assist healthcare providers in organizing waiting lists, optimizing schedules, and managing incoming requests efficiently. By streamlining administrative tasks, Maddie aims to enhance the operational capabilities of health professionals, allowing them to focus more on patient care.

Santé Académie is an innovative online training platform dedicated to enhancing the skills of healthcare professionals. Recognizing the evolving roles of caregivers and the rapid pace of medical knowledge advancement, the company offers high-quality educational videos accessible via web or mobile. Each course is structured into brief episodes lasting 5 to 15 minutes, catering to the busy schedules of doctors, nurses, pharmacists, and care assistants. The curriculum covers essential clinical and regulatory subjects relevant to daily practice, ensuring that participants receive up-to-date information. The courses are certified by the ANDPC and produced by leading experts from esteemed institutions. With a focus on continuous education and engagement, Santé Académie aims to improve patient care throughout the healthcare continuum, a mission supported by over 20,000 professionals and health institutions, including notable organizations such as GHU Paris psychiatrie & neurosciences and Service de Santé des Armées.

Deemea is a developer of a digital medical assistance platform that focuses on enhancing clinical research and the analysis of real-world data. The company utilizes artificial intelligence to streamline various processes, including identifying appropriate databases, expediting contractual and regulatory tasks, and simplifying external model validation. Deemea's platform aims to optimize responses to both internal and external inquiries while valorizing real-world data and clinical studies. By integrating these capabilities, Deemea helps clients accelerate the development and deployment of innovative projects, ensuring efficiency and reliability in the management of imaging data within the clinical research landscape.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Hemerion is a biotechnology company dedicated to developing innovative treatments for cancer, with a particular emphasis on glioblastoma, the most common and aggressive primary brain tumor. The company's platform integrates advanced therapeutic services that combine surgical techniques with photonics, utilizing a photosensitizing drug designed to selectively target and destroy cancer cells. This approach allows for effective treatment in areas that are difficult to reach with traditional surgical methods while preserving healthy tissue. Hemerion's mission is to enhance the capabilities of healthcare professionals in addressing the challenges posed by brain cancer and to improve patient outcomes in their battle against glioblastoma.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and Decentralized Clinical Trial solutions, focused on enhancing the efficiency and quality of data collection in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has specialized in eCOA solutions across various phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. Kayentis has adapted to the evolving clinical research landscape by offering a comprehensive suite of services aimed at supporting science-driven and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, Kayentis provides a range of adaptable tools to streamline electronic data capture, simplifying the clinical trial process for both patients and research sites.

Previa Medical is a health technology company that focuses on predictive medical solutions. The company operates a platform that analyzes real-time data from patients' electronic health records, including laboratory results, vital signs, and medical history. By leveraging FHIR technology, Previa Medical enables healthcare professionals to identify patients at risk of complications, allowing for timely intervention and treatment. This proactive approach aims to enhance patient outcomes and increase survival rates by ensuring that healthcare providers have access to critical information when making clinical decisions.

Previa Medical is a health technology company that focuses on predictive medical solutions. The company operates a platform that analyzes real-time data from patients' electronic health records, including laboratory results, vital signs, and medical history. By leveraging FHIR technology, Previa Medical enables healthcare professionals to identify patients at risk of complications, allowing for timely intervention and treatment. This proactive approach aims to enhance patient outcomes and increase survival rates by ensuring that healthcare providers have access to critical information when making clinical decisions.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutic solutions. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to overcome treatment resistance and enhance cancer cell survival. Their primary focus is on providing effective treatments for gastrointestinal cancers.

Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in the development of advanced medical devices aimed at addressing Ear, Nose, and Throat (ENT) conditions. Dianosic's flagship products include CAVI-T, an asymmetrical intranasal balloon that effectively manages spontaneous or postoperative bleeding through low-pressure compression while adapting to the nasal cavity's unique anatomy. Additionally, the company has developed an Active Resorbable Intranasal Scaffold device designed to treat chronic sinusitis and allergic rhinitis, particularly for patients who have not responded to conventional drug treatments. This innovative scaffold is characterized by its long-acting formulation, which allows for sustained drug release over a period of six to twelve months. Dianosic aims to set new standards of care in ENT treatment, with the potential to expand its technology into other areas such as chronic migraine and facial pain management.

Orthopus manufactures and distributes medical devices. They develop a range of robotic devices for arm mobility. Their supporter compensates for the weight of the arm to facilitate vertical movements. Their robotic device is used in an electric wheelchair and on a table.

WeLinQ is an online platform that provides free consultation services and easy messaging with therapists. They provide a practical substitute for in-person therapy with advantages including anytime messaging, adaptable scheduling, simple therapist switching, and the capacity to take part in sessions from any location.

Elis is a multi-services group operating in Europe and Brazil, specializing in the rental and maintenance of professional clothing, flat linen, and hygiene appliances. The company provides a wide range of tailored solutions, including services for washrooms, floor protection, beverages, cleanrooms, pest control, and medical waste management. With over 19,000 employees across 13 countries, Elis serves more than 240,000 businesses in various sectors, including hospitality, healthcare, industry, retail, and services. The company's extensive network of nearly 300 production and distribution centers, alongside 13 clean rooms, enables it to maintain strong proximity to its clients and deliver high-quality services efficiently. With over a century of experience, Elis has established itself as a leader in cleanliness, image, hygiene, and well-being services.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Ganymed Robotics SAS, established in 2018 and headquartered in Paris, France, specializes in the development of advanced robotics technologies tailored for orthopedic surgeons. The company's primary focus is on creating a therapeutic device designed to enhance surgical precision during knee replacement procedures. This innovative technology aims to improve patient outcomes, surgeon experience, and overall efficiency of care delivery by leveraging robotic assistance to reduce operating time.

Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation. Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.

Remedee Labs SAS is a French company founded in 2016, dedicated to developing innovative solutions for chronic pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a personal endorphin stimulator that facilitates on-demand stimulation of the body’s natural endorphins to alleviate pain. Drawing on a decade of pre-clinical and clinical research, Remedee Labs aims to improve the quality of life for the 1.5 billion people worldwide suffering from chronic pain, particularly focusing on conditions such as fibromyalgia. By collaborating with medical practitioners, the company offers a patient-centered digital service platform that enhances the accessibility and effectiveness of endorphin-stimulation therapy for personal healthcare. As it continues to evolve, Remedee Labs plans to expand its platform to address additional chronic pain conditions, positioning itself as a leader in neuromodulation technology for pain management.

Jalon Therapeutics is a biotechnology company focused on developing innovative therapies that inhibit critical yet untargeted tumor signaling pathways. By exploring non-oncogene addiction, the company aims to identify new therapeutic targets and create effective anticancer treatment strategies. Through its research and development efforts, Jalon Therapeutics is dedicated to transforming the lives of cancer patients by providing novel medications that address unmet medical needs in oncology.

Microphyt is a company focused on researching, developing, producing, and marketing natural algae-based products. It specializes in creating bioactive dietary supplements aimed at promoting weight loss and supporting brain health. The company utilizes an industrial-scale supply of microalgae biomass and extracts, ensuring the preservation of cell integrity while achieving commercial quantities of slow-growing or biofilm-forming species. This approach enables Microphyt to effectively cater to the demands of healthcare industries, particularly in the personal care and food sectors.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in the development of biologic implants utilizing acellular dermis. The company focuses on tissue and cell engineering, creating innovative biological implants designed for tissue repair across various surgical specialties. Their product offerings include the Cellis range, which is tailored for specific surgical needs, such as breast reconstruction and abdominal wall repair. By maintaining a continuous dialogue with surgeons, Meccellis Biotech aims to address unmet clinical needs and provide effective solutions for both practitioners and patients.

Livmed's is a software platform based in Nice, France, that specializes in home medicine delivery services. Founded in 2020, the company enables individuals to receive both prescription and non-prescription medications directly at their homes. The platform operates around the clock, ensuring timely access to essential healthcare products. Livmed's facilitates medicine delivery from local drugstores, allowing customers to obtain their medications conveniently, whether they have a prescription or not. Through its innovative approach, Livmed's enhances accessibility to healthcare while streamlining the medication procurement process for users.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is notable for its lead drug, Glunozumab, a monoclonal antibody that employs a novel mechanism of action. This drug hyperactivates both vascular and neuronal NMDA receptors, leading to off-target toxicity that can disrupt the blood-brain and blood-spinal cord barriers, resulting in neuronal excitotoxicity associated with conditions such as stroke and multiple sclerosis. Lys Therapeutics aims to address neuroinflammation and its effects on neurodegeneration through innovative biotherapies.

Lola Health is an insurance technology company that specializes in providing personalized complementary health insurance solutions. The firm focuses on enhancing traditional insurance offerings by including support for specific care pathways such as endometriosis, parenthood, postpartum depression, psychology, and alternative medicine. Lola Health's services are designed to assist businesses in retaining employees, attracting new talent, and improving overall performance. Key offerings include Angel Plus, an advisory platform that helps employees find solutions, telecommunications services, and psychological support. The company aims to make insurance more accessible and reduce risk by providing numerous assistance and prevention services.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Guerbet is a healthcare company focused on medical imaging, with a history spanning 90 years. As a pioneer in contrast media, it is the only pharmaceutical group dedicated exclusively to this field. Guerbet operates in nearly 80 countries through a network of subsidiaries and distributors, providing a wide array of products for various imaging modalities, including CT scans, magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company’s portfolio includes well-known brands such as Xenetix, Optiray, Dotarem, and Telebrix, among others. Additionally, Guerbet offers injectors and related medical devices aimed at enhancing patient diagnosis, prognosis, and overall quality of life.

BioMAdvanced Diagnostics is a company focused on developing molecular diagnostic and biomarker tests that enhance patient care through individualized treatment strategies. Their innovative tests are designed to integrate seamlessly into existing diagnostic and treatment protocols, ensuring ease of use for healthcare personnel. By providing predictive scores and identifying biomarkers, BioMAdvanced Diagnostics enables clinicians to assess the immune response of patients and evaluate the risk of transplant rejection. This capability allows for improved anticipation and adaptation of treatment plans, ultimately aiming to enhance patient outcomes significantly.

Incepto Medical SAS, established in 2018 and headquartered in Paris, France, specializes in developing and distributing artificial intelligence (AI) applications for medical imaging. Its portfolio includes software solutions like Qure.ai qER and qXR for head CT and thorax abnormality detection, Aidence Veye Chest for pulmonary nodule tracking, Icometric Icobrain for neurological disorder monitoring, and ScreenPoint Transpara for breast cancer detection. Additionally, Incepto operates Collective Minds Radiology, an online platform fostering case support, opinion sharing, and learning among healthcare professionals. The company aims to empower medical practitioners by providing AI-driven tools that address the challenges posed by increasing patient volumes and image data.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

Cuure is a company specializing in personalized vitamins and supplements designed to meet individual health needs. Through a combination of health questionnaires and DNA analysis, Cuure creates customized supplement plans aimed at optimizing overall wellness. The company's platform offers tailored recommendations based on scientific research, ensuring that users receive the appropriate dosages of vitamins, minerals, and plant-based ingredients suited to their specific health goals and body chemistry. Additionally, Cuure incorporates a tracking application to help individuals foster wellness habits, making it easier for them to integrate these personalized solutions into their daily routines.

Apmonia Therapeutics is a biotechnology company focused on developing next-generation peptide-based therapies aimed at targeting the tumor microenvironment to enhance cancer treatment. The company is dedicated to creating innovative drugs for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. By offering new therapeutic perspectives, Apmonia aims to improve the lives of cancer patients and support researchers in developing personalized immunotherapy approaches. Their proprietary therapeutic peptides are designed to provide effective strategies for treating solid tumors, thereby contributing to advanced cancer care.

DeepLife is a biotech company founded in 2019 and based in Paris, France. The company specializes in developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This innovative approach aims to identify new targets, biomarkers, and potential drug candidates, while also addressing drug resistance and sensitivity. DeepLife operates in a collaborative manner, working alongside academic institutions to ensure a smooth transition from laboratory discoveries to patient applications. The company focuses on leveraging state-of-the-art technologies in systems biology and machine learning to identify molecular triggers that restore cells to their healthy states, thereby accelerating the target identification processes for biotech and pharmaceutical firms.

Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.

Qairn is a company that specializes in digitizing regulatory processes through its software-as-a-service (SaaS) platform. This platform is designed to streamline and secure mandatory procedures for various healthcare sectors, including laboratories, medical device manufacturers, and biotechnology firms. Qairn offers services such as the review and validation of promotional materials, submission to the ANSM, and the validation of regulated content. By simplifying these processes, Qairn helps healthcare manufacturers manage their regulatory requirements efficiently, thereby reducing risks associated with compliance and enhancing workflow management.

SPART supports companies in the process of improving quality of life at work by offering solutions to activate health and well-being practices each day in a professional environment. They are partners for corporate sporting challenges. They enable everyone to achieve their full potential through innovative physical activities within the company.

Nurea is a company that focuses on providing decision-making support solutions for healthcare professionals, particularly vascular surgeons. It specializes in the development of medical imaging software aimed at the diagnosis of vascular diseases. Nurea's platform automates the analysis of medical images, offering accurate quantitative assessments and decision indicators that assist in managing patient groups during both pre and post-operative monitoring. By streamlining the workflow associated with full-body scan analysis, Nurea enables surgeons to simplify their decision-making processes and improve patient outcomes in the context of cardiovascular diseases.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women through innovative regenerative medicine techniques. The company specializes in creating bioprostheses using 3D bioprinting technology, offering an alternative to traditional breast reconstruction methods. By focusing on natural products, Healshape aims to provide women with long-lasting, aesthetically pleasing results, helping them regain their self-confidence following surgery.

Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.

Implicity is a developer of a remote monitoring platform that focuses on patients with connected cardiac implants, such as pacemakers and defibrillators. The company's software-as-a-service (SaaS) platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on the medical context of each individual. This technology allows cardiologists and healthcare professionals to automate the monitoring process, facilitating efficient oversight of patient health and enhancing the quality of care. By consolidating patient information and alerts on a single platform, Implicity aims to improve the management of cardiac conditions and support hospital teams in delivering optimal patient outcomes.

Hemerion is a biotechnology company dedicated to developing innovative treatments for cancer, with a particular emphasis on glioblastoma, the most common and aggressive primary brain tumor. The company's platform integrates advanced therapeutic services that combine surgical techniques with photonics, utilizing a photosensitizing drug designed to selectively target and destroy cancer cells. This approach allows for effective treatment in areas that are difficult to reach with traditional surgical methods while preserving healthy tissue. Hemerion's mission is to enhance the capabilities of healthcare professionals in addressing the challenges posed by brain cancer and to improve patient outcomes in their battle against glioblastoma.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

Guard Medical is a medical device company specializing in the development of NPseal™, an innovative solution aimed at improving postoperative wound care. The device is designed to reduce the risk of surgical site infections while enhancing the healing process for closed surgical incisions. By utilizing an integrated pump, NPseal™ establishes and maintains negative pressure with ease, facilitating prophylactic negative pressure wound therapy (NPWT). This approach not only helps prevent infection and minimizes scarring but also enhances the overall cosmetic outcome of surgical wounds. Guard Medical's focus on creating user-friendly and cost-effective solutions positions it as a key player in the medical device industry.